0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Transdermal Scopolamine Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-31K4124
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Transdermal Scopolamine Market Insights and Forecast to 2028
BUY CHAPTERS

Global Transdermal Scopolamine Market Research Report 2025

Code: QYRE-Auto-31K4124
Report
September 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Transdermal Scopolamine Market Size

The global market for Transdermal Scopolamine was valued at US$ 428 million in the year 2024 and is projected to reach a revised size of US$ 585 million by 2031, growing at a CAGR of 4.6% during the forecast period.

Transdermal Scopolamine Market

Transdermal Scopolamine Market

Scopolamine transdermal patch is used to prevent nausea and vomiting after anesthesia, narcotic pain medicines, and surgery. It is also used to prevent nausea and vomiting caused by motion sickness. Scopolamine belongs to the group of medicines called anticholinergics.
The fluctuation of upstream raw material prices has a significant impact on product prices.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Transdermal Scopolamine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transdermal Scopolamine.
The Transdermal Scopolamine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Transdermal Scopolamine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Transdermal Scopolamine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Transdermal Scopolamine Market Report

Report Metric Details
Report Name Transdermal Scopolamine Market
Accounted market size in year US$ 428 million
Forecasted market size in 2031 US$ 585 million
CAGR 4.6%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Tablet Type
  • Syrups Type
  • Injections Type
  • Patch Type
  • Gel Type
Segment by Application
  • Narcotic Analgesia
  • Cough
  • Asthma
  • Motion Sickness
  • Parkinson's Disease
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Baxter International, GlaxoSmithKline, Novartis AG, Perrigo Company, Caleb Pharmaceuticals, Myungmoon Pharma, Pfizer, Nichi-Iko
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Transdermal Scopolamine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Transdermal Scopolamine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Transdermal Scopolamine Market growing?

Ans: The Transdermal Scopolamine Market witnessing a CAGR of 4.6% during the forecast period 2025-2031.

What is the Transdermal Scopolamine Market size in 2031?

Ans: The Transdermal Scopolamine Market size in 2031 will be US$ 585 million.

Who are the main players in the Transdermal Scopolamine Market report?

Ans: The main players in the Transdermal Scopolamine Market are Baxter International, GlaxoSmithKline, Novartis AG, Perrigo Company, Caleb Pharmaceuticals, Myungmoon Pharma, Pfizer, Nichi-Iko

What are the Application segmentation covered in the Transdermal Scopolamine Market report?

Ans: The Applications covered in the Transdermal Scopolamine Market report are Narcotic Analgesia, Cough, Asthma, Motion Sickness, Parkinson's Disease, Others

What are the Type segmentation covered in the Transdermal Scopolamine Market report?

Ans: The Types covered in the Transdermal Scopolamine Market report are Tablet Type, Syrups Type, Injections Type, Patch Type, Gel Type

1 Transdermal Scopolamine Market Overview
1.1 Product Definition
1.2 Transdermal Scopolamine by Type
1.2.1 Global Transdermal Scopolamine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Tablet Type
1.2.3 Syrups Type
1.2.4 Injections Type
1.2.5 Patch Type
1.2.6 Gel Type
1.3 Transdermal Scopolamine by Application
1.3.1 Global Transdermal Scopolamine Market Value by Application (2024 VS 2031)
1.3.2 Narcotic Analgesia
1.3.3 Cough
1.3.4 Asthma
1.3.5 Motion Sickness
1.3.6 Parkinson's Disease
1.3.7 Others
1.4 Global Transdermal Scopolamine Market Size Estimates and Forecasts
1.4.1 Global Transdermal Scopolamine Revenue 2020-2031
1.4.2 Global Transdermal Scopolamine Sales 2020-2031
1.4.3 Global Transdermal Scopolamine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Transdermal Scopolamine Market Competition by Manufacturers
2.1 Global Transdermal Scopolamine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Transdermal Scopolamine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Transdermal Scopolamine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Transdermal Scopolamine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Transdermal Scopolamine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Transdermal Scopolamine, Product Type & Application
2.7 Global Key Manufacturers of Transdermal Scopolamine, Date of Enter into This Industry
2.8 Global Transdermal Scopolamine Market Competitive Situation and Trends
2.8.1 Global Transdermal Scopolamine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Transdermal Scopolamine Players Market Share by Revenue
2.8.3 Global Transdermal Scopolamine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Transdermal Scopolamine Market Scenario by Region
3.1 Global Transdermal Scopolamine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Transdermal Scopolamine Sales by Region: 2020-2031
3.2.1 Global Transdermal Scopolamine Sales by Region: 2020-2025
3.2.2 Global Transdermal Scopolamine Sales by Region: 2026-2031
3.3 Global Transdermal Scopolamine Revenue by Region: 2020-2031
3.3.1 Global Transdermal Scopolamine Revenue by Region: 2020-2025
3.3.2 Global Transdermal Scopolamine Revenue by Region: 2026-2031
3.4 North America Transdermal Scopolamine Market Facts & Figures by Country
3.4.1 North America Transdermal Scopolamine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Transdermal Scopolamine Sales by Country (2020-2031)
3.4.3 North America Transdermal Scopolamine Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Transdermal Scopolamine Market Facts & Figures by Country
3.5.1 Europe Transdermal Scopolamine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Transdermal Scopolamine Sales by Country (2020-2031)
3.5.3 Europe Transdermal Scopolamine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Transdermal Scopolamine Market Facts & Figures by Region
3.6.1 Asia Pacific Transdermal Scopolamine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Transdermal Scopolamine Sales by Region (2020-2031)
3.6.3 Asia Pacific Transdermal Scopolamine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Transdermal Scopolamine Market Facts & Figures by Country
3.7.1 Latin America Transdermal Scopolamine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Transdermal Scopolamine Sales by Country (2020-2031)
3.7.3 Latin America Transdermal Scopolamine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Transdermal Scopolamine Market Facts & Figures by Country
3.8.1 Middle East and Africa Transdermal Scopolamine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Transdermal Scopolamine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Transdermal Scopolamine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Transdermal Scopolamine Sales by Type (2020-2031)
4.1.1 Global Transdermal Scopolamine Sales by Type (2020-2025)
4.1.2 Global Transdermal Scopolamine Sales by Type (2026-2031)
4.1.3 Global Transdermal Scopolamine Sales Market Share by Type (2020-2031)
4.2 Global Transdermal Scopolamine Revenue by Type (2020-2031)
4.2.1 Global Transdermal Scopolamine Revenue by Type (2020-2025)
4.2.2 Global Transdermal Scopolamine Revenue by Type (2026-2031)
4.2.3 Global Transdermal Scopolamine Revenue Market Share by Type (2020-2031)
4.3 Global Transdermal Scopolamine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Transdermal Scopolamine Sales by Application (2020-2031)
5.1.1 Global Transdermal Scopolamine Sales by Application (2020-2025)
5.1.2 Global Transdermal Scopolamine Sales by Application (2026-2031)
5.1.3 Global Transdermal Scopolamine Sales Market Share by Application (2020-2031)
5.2 Global Transdermal Scopolamine Revenue by Application (2020-2031)
5.2.1 Global Transdermal Scopolamine Revenue by Application (2020-2025)
5.2.2 Global Transdermal Scopolamine Revenue by Application (2026-2031)
5.2.3 Global Transdermal Scopolamine Revenue Market Share by Application (2020-2031)
5.3 Global Transdermal Scopolamine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Baxter International
6.1.1 Baxter International Company Information
6.1.2 Baxter International Description and Business Overview
6.1.3 Baxter International Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Baxter International Transdermal Scopolamine Product Portfolio
6.1.5 Baxter International Recent Developments/Updates
6.2 GlaxoSmithKline
6.2.1 GlaxoSmithKline Company Information
6.2.2 GlaxoSmithKline Description and Business Overview
6.2.3 GlaxoSmithKline Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GlaxoSmithKline Transdermal Scopolamine Product Portfolio
6.2.5 GlaxoSmithKline Recent Developments/Updates
6.3 Novartis AG
6.3.1 Novartis AG Company Information
6.3.2 Novartis AG Description and Business Overview
6.3.3 Novartis AG Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novartis AG Transdermal Scopolamine Product Portfolio
6.3.5 Novartis AG Recent Developments/Updates
6.4 Perrigo Company
6.4.1 Perrigo Company Company Information
6.4.2 Perrigo Company Description and Business Overview
6.4.3 Perrigo Company Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Perrigo Company Transdermal Scopolamine Product Portfolio
6.4.5 Perrigo Company Recent Developments/Updates
6.5 Caleb Pharmaceuticals
6.5.1 Caleb Pharmaceuticals Company Information
6.5.2 Caleb Pharmaceuticals Description and Business Overview
6.5.3 Caleb Pharmaceuticals Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Caleb Pharmaceuticals Transdermal Scopolamine Product Portfolio
6.5.5 Caleb Pharmaceuticals Recent Developments/Updates
6.6 Myungmoon Pharma
6.6.1 Myungmoon Pharma Company Information
6.6.2 Myungmoon Pharma Description and Business Overview
6.6.3 Myungmoon Pharma Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Myungmoon Pharma Transdermal Scopolamine Product Portfolio
6.6.5 Myungmoon Pharma Recent Developments/Updates
6.7 Pfizer
6.7.1 Pfizer Company Information
6.7.2 Pfizer Description and Business Overview
6.7.3 Pfizer Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Pfizer Transdermal Scopolamine Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Nichi-Iko
6.8.1 Nichi-Iko Company Information
6.8.2 Nichi-Iko Description and Business Overview
6.8.3 Nichi-Iko Transdermal Scopolamine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Nichi-Iko Transdermal Scopolamine Product Portfolio
6.8.5 Nichi-Iko Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Transdermal Scopolamine Industry Chain Analysis
7.2 Transdermal Scopolamine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Transdermal Scopolamine Production Mode & Process Analysis
7.4 Transdermal Scopolamine Sales and Marketing
7.4.1 Transdermal Scopolamine Sales Channels
7.4.2 Transdermal Scopolamine Distributors
7.5 Transdermal Scopolamine Customer Analysis
8 Transdermal Scopolamine Market Dynamics
8.1 Transdermal Scopolamine Industry Trends
8.2 Transdermal Scopolamine Market Drivers
8.3 Transdermal Scopolamine Market Challenges
8.4 Transdermal Scopolamine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Transdermal Scopolamine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Transdermal Scopolamine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Transdermal Scopolamine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Transdermal Scopolamine Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Transdermal Scopolamine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Transdermal Scopolamine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Transdermal Scopolamine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Transdermal Scopolamine Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Transdermal Scopolamine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Transdermal Scopolamine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Transdermal Scopolamine, Product Type & Application
 Table 12. Global Key Manufacturers of Transdermal Scopolamine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Transdermal Scopolamine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transdermal Scopolamine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Transdermal Scopolamine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Transdermal Scopolamine Sales by Region (2020-2025) & (K Units)
 Table 18. Global Transdermal Scopolamine Sales Market Share by Region (2020-2025)
 Table 19. Global Transdermal Scopolamine Sales by Region (2026-2031) & (K Units)
 Table 20. Global Transdermal Scopolamine Sales Market Share by Region (2026-2031)
 Table 21. Global Transdermal Scopolamine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Transdermal Scopolamine Revenue Market Share by Region (2020-2025)
 Table 23. Global Transdermal Scopolamine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Transdermal Scopolamine Revenue Market Share by Region (2026-2031)
 Table 25. North America Transdermal Scopolamine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Transdermal Scopolamine Sales by Country (2020-2025) & (K Units)
 Table 27. North America Transdermal Scopolamine Sales by Country (2026-2031) & (K Units)
 Table 28. North America Transdermal Scopolamine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Transdermal Scopolamine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Transdermal Scopolamine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Transdermal Scopolamine Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Transdermal Scopolamine Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Transdermal Scopolamine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Transdermal Scopolamine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Transdermal Scopolamine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Transdermal Scopolamine Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Transdermal Scopolamine Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Transdermal Scopolamine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Transdermal Scopolamine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Transdermal Scopolamine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Transdermal Scopolamine Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Transdermal Scopolamine Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Transdermal Scopolamine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Transdermal Scopolamine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Transdermal Scopolamine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Transdermal Scopolamine Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Transdermal Scopolamine Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Transdermal Scopolamine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Transdermal Scopolamine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Transdermal Scopolamine Sales (K Units) by Type (2020-2025)
 Table 51. Global Transdermal Scopolamine Sales (K Units) by Type (2026-2031)
 Table 52. Global Transdermal Scopolamine Sales Market Share by Type (2020-2025)
 Table 53. Global Transdermal Scopolamine Sales Market Share by Type (2026-2031)
 Table 54. Global Transdermal Scopolamine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Transdermal Scopolamine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Transdermal Scopolamine Revenue Market Share by Type (2020-2025)
 Table 57. Global Transdermal Scopolamine Revenue Market Share by Type (2026-2031)
 Table 58. Global Transdermal Scopolamine Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Transdermal Scopolamine Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Transdermal Scopolamine Sales (K Units) by Application (2020-2025)
 Table 61. Global Transdermal Scopolamine Sales (K Units) by Application (2026-2031)
 Table 62. Global Transdermal Scopolamine Sales Market Share by Application (2020-2025)
 Table 63. Global Transdermal Scopolamine Sales Market Share by Application (2026-2031)
 Table 64. Global Transdermal Scopolamine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Transdermal Scopolamine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Transdermal Scopolamine Revenue Market Share by Application (2020-2025)
 Table 67. Global Transdermal Scopolamine Revenue Market Share by Application (2026-2031)
 Table 68. Global Transdermal Scopolamine Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Transdermal Scopolamine Price (USD/Unit) by Application (2026-2031)
 Table 70. Baxter International Company Information
 Table 71. Baxter International Description and Business Overview
 Table 72. Baxter International Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Baxter International Transdermal Scopolamine Product
 Table 74. Baxter International Recent Developments/Updates
 Table 75. GlaxoSmithKline Company Information
 Table 76. GlaxoSmithKline Description and Business Overview
 Table 77. GlaxoSmithKline Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. GlaxoSmithKline Transdermal Scopolamine Product
 Table 79. GlaxoSmithKline Recent Developments/Updates
 Table 80. Novartis AG Company Information
 Table 81. Novartis AG Description and Business Overview
 Table 82. Novartis AG Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. Novartis AG Transdermal Scopolamine Product
 Table 84. Novartis AG Recent Developments/Updates
 Table 85. Perrigo Company Company Information
 Table 86. Perrigo Company Description and Business Overview
 Table 87. Perrigo Company Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Perrigo Company Transdermal Scopolamine Product
 Table 89. Perrigo Company Recent Developments/Updates
 Table 90. Caleb Pharmaceuticals Company Information
 Table 91. Caleb Pharmaceuticals Description and Business Overview
 Table 92. Caleb Pharmaceuticals Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Caleb Pharmaceuticals Transdermal Scopolamine Product
 Table 94. Caleb Pharmaceuticals Recent Developments/Updates
 Table 95. Myungmoon Pharma Company Information
 Table 96. Myungmoon Pharma Description and Business Overview
 Table 97. Myungmoon Pharma Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Myungmoon Pharma Transdermal Scopolamine Product
 Table 99. Myungmoon Pharma Recent Developments/Updates
 Table 100. Pfizer Company Information
 Table 101. Pfizer Description and Business Overview
 Table 102. Pfizer Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Pfizer Transdermal Scopolamine Product
 Table 104. Pfizer Recent Developments/Updates
 Table 105. Nichi-Iko Company Information
 Table 106. Nichi-Iko Description and Business Overview
 Table 107. Nichi-Iko Transdermal Scopolamine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Nichi-Iko Transdermal Scopolamine Product
 Table 109. Nichi-Iko Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Transdermal Scopolamine Distributors List
 Table 113. Transdermal Scopolamine Customers List
 Table 114. Transdermal Scopolamine Market Trends
 Table 115. Transdermal Scopolamine Market Drivers
 Table 116. Transdermal Scopolamine Market Challenges
 Table 117. Transdermal Scopolamine Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Transdermal Scopolamine
 Figure 2. Global Transdermal Scopolamine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Transdermal Scopolamine Market Share by Type: 2024 & 2031
 Figure 4. Tablet Type Product Picture
 Figure 5. Syrups Type Product Picture
 Figure 6. Injections Type Product Picture
 Figure 7. Patch Type Product Picture
 Figure 8. Gel Type Product Picture
 Figure 9. Global Transdermal Scopolamine Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global Transdermal Scopolamine Market Share by Application: 2024 & 2031
 Figure 11. Narcotic Analgesia
 Figure 12. Cough
 Figure 13. Asthma
 Figure 14. Motion Sickness
 Figure 15. Parkinson's Disease
 Figure 16. Others
 Figure 17. Global Transdermal Scopolamine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global Transdermal Scopolamine Market Size (2020-2031) & (US$ Million)
 Figure 19. Global Transdermal Scopolamine Sales (2020-2031) & (K Units)
 Figure 20. Global Transdermal Scopolamine Average Price (USD/Unit) & (2020-2031)
 Figure 21. Transdermal Scopolamine Report Years Considered
 Figure 22. Transdermal Scopolamine Sales Share by Manufacturers in 2024
 Figure 23. Global Transdermal Scopolamine Revenue Share by Manufacturers in 2024
 Figure 24. Global 5 and 10 Largest Transdermal Scopolamine Players: Market Share by Revenue in Transdermal Scopolamine in 2024
 Figure 25. Transdermal Scopolamine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 26. Global Transdermal Scopolamine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 27. North America Transdermal Scopolamine Sales Market Share by Country (2020-2031)
 Figure 28. North America Transdermal Scopolamine Revenue Market Share by Country (2020-2031)
 Figure 29. U.S. Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Canada Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Europe Transdermal Scopolamine Sales Market Share by Country (2020-2031)
 Figure 32. Europe Transdermal Scopolamine Revenue Market Share by Country (2020-2031)
 Figure 33. Germany Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. France Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. U.K. Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Italy Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Russia Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Asia Pacific Transdermal Scopolamine Sales Market Share by Region (2020-2031)
 Figure 39. Asia Pacific Transdermal Scopolamine Revenue Market Share by Region (2020-2031)
 Figure 40. China Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Japan Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. South Korea Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. India Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Australia Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. China Taiwan Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Indonesia Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Thailand Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Malaysia Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Latin America Transdermal Scopolamine Sales Market Share by Country (2020-2031)
 Figure 50. Latin America Transdermal Scopolamine Revenue Market Share by Country (2020-2031)
 Figure 51. Mexico Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Brazil Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Argentina Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Middle East and Africa Transdermal Scopolamine Sales Market Share by Country (2020-2031)
 Figure 55. Middle East and Africa Transdermal Scopolamine Revenue Market Share by Country (2020-2031)
 Figure 56. Turkey Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. Saudi Arabia Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. UAE Transdermal Scopolamine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 59. Global Sales Market Share of Transdermal Scopolamine by Type (2020-2031)
 Figure 60. Global Revenue Market Share of Transdermal Scopolamine by Type (2020-2031)
 Figure 61. Global Transdermal Scopolamine Price (USD/Unit) by Type (2020-2031)
 Figure 62. Global Sales Market Share of Transdermal Scopolamine by Application (2020-2031)
 Figure 63. Global Revenue Market Share of Transdermal Scopolamine by Application (2020-2031)
 Figure 64. Global Transdermal Scopolamine Price (USD/Unit) by Application (2020-2031)
 Figure 65. Transdermal Scopolamine Value Chain
 Figure 66. Channels of Distribution (Direct Vs Distribution)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS